COMMON STOCK PURCHASE WARRANTSecurity Agreement • August 9th, 2018 • CareDx, Inc. • Services-medical laboratories • New York
This Warrant is issued pursuant to that certain Credit Agreement and Guaranty dated as of April 17, 2018 (the “Credit Agreement”) by and among the Company, as borrower, the subsidiaries of the Company from time to time party thereto as guarantors, the lenders from time to time party thereto, and Holder, as administrative agent for the lenders.
Credit Agreement and Guaranty dated as of April 17, 2018 among CareDx, Inc. as the Borrower, Certain Subsidiaries of the Borrower from Time to Time Party hereto, as the Subsidiary Guarantors, The Lenders from Time to Time Party hereto, as the Lenders,...Credit Agreement • August 9th, 2018 • CareDx, Inc. • Services-medical laboratories • New York
LICENSE AND COMMERCIALIZATION AGREEMENTLicense and Commercialization Agreement • August 9th, 2018 • CareDx, Inc. • Services-medical laboratories • California
This License and Commercialization Agreement (“Agreement”) is effective as of the date of last signature below (the “Effective Date”) by and between Illumina, Inc., a Delaware corporation, having a place of business at 5200 Illumina Way, San Diego, CA, 92122 (“Illumina”), and CareDx, Inc., a Delaware corporation, having a place of business at 3260 Bayshore Boulevard, Brisbane, CA 94005 (“CareDx”). Illumina and CareDx may each be referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
Dr. Peter Maag Chief Executive Officer CareDx, Inc. Brisbane, CA 94005 Dear Dr. Maag:Senior Term Loan Facility Agreement • August 9th, 2018 • CareDx, Inc. • Services-medical laboratories
CareDx, Inc. (the “Borrower”) has requested the commitment of Perceptive Credit Holdings II, LP (the “Lender” or “Perceptive”) to provide financing to the Borrower in the form of a Senior Term Loan Facility in an aggregate principal amount not to exceed $35,000,000 (the “Facility”). Perceptive has agreed to provide such commitment on the terms set forth in this letter (the “Commitment Letter”). The proceeds of the Facility will be used for general corporate purposes, including, without limitation, business development and licensing purposes, the refinancing of existing debt and the payment of fees and expenses associated with the negotiation, execution and implementation of the Facility. The terms and provisions governing the Facility will be substantially as set forth in the draft of the documents set forth on Exhibit A hereto, with such changes which have been previously agreed to by the parties and further changes which are satisfactory to the Lender in its reasonable discretion, in
